Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - deferasirox, quantity: 180 mg - tablet, film coated - excipient ingredients: crospovidone; poloxamer; colloidal anhydrous silica; magnesium stearate; microcrystalline cellulose; povidone; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. alembic deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,alembic deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - deferasirox, quantity: 90 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; magnesium stearate; colloidal anhydrous silica; poloxamer; crospovidone; povidone; sodium starch glycollate type a; titanium dioxide; hypromellose; purified talc; macrogol 4000; indigo carmine aluminium lake - the treatment of chronic iron overload due to blood transfusions (transfusional haemosiderosis) in adults and paediatric patients 6 years and older. alembic deferasirox is also indicated for the treatment of chronic iron overload in paediatric patients aged 2 to 5 years who are unable to take desferrioxamine therapy or in whom desferrioxamine has proven ineffective. ,alembic deferasirox is also indicated for the treatment of chronic iron overload in patients with non-transfusion- dependent thalassemia syndromes aged 10 years and older.

Zimbabwe - Inggeris - Medicines Control Authority

alembic pharmaceuticals limited - amlodipine; valsartan - tablet, coated; oral - 10; 160mg

Malta - Inggeris - Medicines Authority

alembic pharmaceuticals europe limited palazzo pietro stiges, 103, strait street, valletta vlt 1436, malta - celecoxib - hard capsule - celecoxib 100 mg - antiinflammatory and antirheumatic products

Malta - Inggeris - Medicines Authority

alembic pharmaceuticals europe limited palazzo pietro stiges, 103, strait street, valletta vlt 1436, malta - celecoxib - hard capsule - celecoxib 200 mg - antiinflammatory and antirheumatic products

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - olmesartan medoxomil, quantity: 20 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: hyprolose; magnesium stearate; hypromellose; purified water; microcrystalline cellulose; lactose monohydrate; titanium dioxide; iron oxide yellow; macrogol 4000 - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - olmesartan medoxomil, quantity: 40 mg; hydrochlorothiazide, quantity: 25 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hyprolose; microcrystalline cellulose; hypromellose; purified water; titanium dioxide; iron oxide yellow; macrogol 4000 - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 20 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; hypromellose; lactose monohydrate; purified water; magnesium stearate; hyprolose; titanium dioxide; iron oxide yellow; macrogol 4000 - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - hydrochlorothiazide, quantity: 12.5 mg; olmesartan medoxomil, quantity: 40 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; hypromellose; microcrystalline cellulose; hyprolose; purified water; titanium dioxide; iron oxide yellow; macrogol 4000 - treatment of hypertension. treatment should not be initiated with this fixed dose combination.

Australia - Inggeris - Department of Health (Therapeutic Goods Administration)

alembic pharmaceuticals australia pty ltd - venlafaxine hydrochloride, quantity: 254.7 mg (equivalent: venlafaxine, qty 225 mg) - capsule, modified release - excipient ingredients: microcrystalline cellulose; povidone; purified talc; colloidal anhydrous silica; magnesium stearate; ethylcellulose; copovidone; carmoisine; titanium dioxide; gelatin; propylene glycol; indigo carmine; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution - venlafaxine extended release capsule is indicated for the treatment of: major depression, including prevention of relapse and recurrence where appropriate; generalised anxiety disorder; social anxiety disorder; panic disorder, including prevention of relapse.